Gland Pharma Ltd
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
- Market Cap ₹ 30,726 Cr.
- Current Price ₹ 1,865
- High / Low ₹ 2,221 / 1,475
- Stock P/E 42.5
- Book Value ₹ 530
- Dividend Yield 1.06 %
- ROCE 13.6 %
- ROE 9.26 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Promoter holding has decreased over last quarter: -6.03%
- Company has a low return on equity of 12.5% over last 3 years.
- Dividend payout has been low at 14.2% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|
2,633 | 3,463 | 4,401 | 3,625 | 5,665 | 5,858 | |
1,678 | 2,161 | 2,890 | 2,600 | 4,332 | 4,554 | |
Operating Profit | 955 | 1,302 | 1,510 | 1,025 | 1,333 | 1,304 |
OPM % | 36% | 38% | 34% | 28% | 24% | 22% |
139 | 135 | 224 | 184 | 170 | 184 | |
Interest | 7 | 3 | 5 | 7 | 26 | 27 |
Depreciation | 95 | 99 | 110 | 147 | 345 | 371 |
Profit before tax | 993 | 1,335 | 1,619 | 1,055 | 1,133 | 1,090 |
Tax % | 22% | 25% | 25% | 26% | 32% | |
773 | 997 | 1,212 | 781 | 772 | 722 | |
EPS in Rs | 49.88 | 60.94 | 73.75 | 47.42 | 46.90 | 43.84 |
Dividend Payout % | 0% | 0% | 0% | 0% | 43% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 18% |
TTM: | 47% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -8% |
TTM: | -7% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -22% |
1 Year: | 11% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 12% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 16 | 16 | 16 | 16 | 16 |
Reserves | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 |
5 | 5 | 5 | 4 | 372 | |
435 | 588 | 671 | 814 | 1,515 | |
Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 |
968 | 954 | 1,502 | 1,571 | 3,947 | |
CWIP | 188 | 338 | 191 | 177 | 238 |
Investments | 0 | 0 | 155 | 0 | 0 |
2,929 | 5,204 | 5,986 | 7,030 | 6,426 | |
Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
701 | 605 | 791 | 364 | 997 | |
-761 | -1,520 | -999 | 1,211 | -1,749 | |
-7 | 1,238 | 35 | 15 | -799 | |
Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 83 | 71 | 89 | 88 | 100 |
Inventory Days | 250 | 312 | 205 | 421 | 278 |
Days Payable | 82 | 97 | 80 | 127 | 145 |
Cash Conversion Cycle | 251 | 286 | 214 | 382 | 234 |
Working Capital Days | 161 | 169 | 168 | 242 | 170 |
ROCE % | 28% | 25% | 15% | 14% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Sep
-
Announcement under Regulation 30 (LODR)-Change in Management
10 Sep - Changes among Senior management Personnel of the Company
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
9 Sep - Regarding Analyst/Investor Meet scheduled on September 11, 2024
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Sep - Regarding Schedule of Analyst/Investor Meet on September 09, 2024
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 30 Aug
Annual reports
Concalls
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Jul 2022Transcript PPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
Revenue breakup
Gland Pharma is primarily a contract manufacturer of injectables, with B2B segment generating ~95% of revenues in FY22 [1]